Rafferty Asset Management’s KalVista Pharmaceuticals KALV Stock Holding History

Rafferty Asset Management’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.15M	Sell	57,296 -8,297	-13%	-$134K	﹤0.01%	726
2025 Q4	$1.06M	Buy	65,593 +7,803	+14%	+$103K	﹤0.01%	787
2025 Q3	$704K	Buy	57,790 +10,889	+23%	+$150K	﹤0.01%	848
2025 Q2	$530K	Buy	46,901 +20,632	+79%	+$252K	﹤0.01%	875
2025 Q1	$303K	Sell	26,269 -28,197	-52%	-$288K	﹤0.01%	964
2024 Q4	$461K	Buy	54,466 +10,636	+24%	+$110K	﹤0.01%	927
2024 Q3	$508K	Buy	+43,830	New	+$551K	﹤0.01%	926
2022 Q2	–	Sell	-47,549	Closed	-$701K	–	1179
2022 Q1	$701K	Sell	47,549 -16,637	-26%	-$239K	﹤0.01%	860
2021 Q4	$849K	Buy	64,186 +25,586	+66%	+$407K	﹤0.01%	943
2021 Q3	$674K	Sell	38,600 -21,124	-35%	-$428K	﹤0.01%	976
2021 Q2	$1.43M	Buy	59,724 +41,425	+226%	+$1.08M	0.01%	777
2021 Q1	$470K	Buy	+18,299	New	+$481K	﹤0.01%	981

Other funds holding KALV

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Rafferty Asset Management's KALV Position: Q1 2026 in Review

Rafferty Asset Management reduced its KalVista Pharmaceuticals (KALV) stake by 13% in Q1 2026, selling an estimated $134K and leaving 57,296 shares worth $1.15M. The position accounts for ﹤0.01% of the portfolio, ranked #726.

Rafferty Asset Management first reported a position in KALV in Q1 2021 and has held it in 12 quarters since. The position peaked at $1.43M in Q2 2021. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

Rafferty Asset Management held 57,296 shares of KalVista Pharmaceuticals worth $1.15M as of Q1 2026.
Rafferty Asset Management sold 8,297 KalVista Pharmaceuticals shares in Q1 2026, an estimated $134K.
KalVista Pharmaceuticals made up ﹤0.01% of Rafferty Asset Management's portfolio in Q1 2026, its #726 holding.
Rafferty Asset Management first reported a position in KalVista Pharmaceuticals in Q1 2021 and has held it in 12 quarters since.
Rafferty Asset Management's KalVista Pharmaceuticals position peaked at $1.43M in Q2 2021.
183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Rafferty Asset Management's 13F filing for Q1 2026, filed 15 May 2026.